Market Closed - London S.E. 11:35:26 2024-05-01 am EDT 5-day change 1st Jan Change
976.6 GBX -0.25% Intraday chart for Smith & Nephew Plc -0.83% -9.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
London Stocks Retreat as UK Manufacturing Sector Reverts to Contraction MT
FTSE 100 treads water as Fed takes centre-stage AN
Smith & Nephew confident for full-year despite mixed first quarter AN
FTSE 100 shakes off New York slump before Fed AN
Transcript : Smith & Nephew plc, Q1 2024 Sales/ Trading Statement Call, May 01, 2024
Smith & Nephew Logs Higher Q1 Revenue; FY24 Guidance Affirmed MT
Earnings Flash (SN.L) SMITH & NEPHEW Posts Q1 Revenue $1.39B MT
UK Stocks Retreat as Hope for June BoE Rate Cut Dissipates MT
Proxy Advisers Raise Concerns Over Smith & Nephew's Pay Hike Proposal MT
Smith+Nephew, Navbit Sign Distribution Deal for Hip Replacement Surgical Navigation System in Australia MT
Smith & Nephew Says UK NICE Reaffirms Guidance on Pico Wound Dressing MT
Miach Orthopaedics Inc. announced that it has received $50 million in funding from a group of investors CI
Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System CI
London stocks round off March quarter with healthy gains RE
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday MT
Smith & Nephew CFO designate John Rogers to start next week AN
Smith & Nephew CFO to Take Office in April MT
Smith & Nephew plc Announces CFO Changes CI
Smith & Nephew plc Announces Board Changes CI
Smith & Nephew Signs Up as Official Partner for UFC MT
Smith+Nephew Teams Up with Ufc to Be First-Ever Preferred Sports Medicine Technology Partner CI
Smith & Nephew prices USD1 billion in debt notes AN
Smith & Nephew plc Completes the Pricing of Usd 350,000,000 5.150% Notes Due 2027 and Usd 650,000,000 5.400% Notes Due 2034 CI
Smith & Nephew Prices Offering of Notes due 2027, 2034 MT
UK's Smith & Nephew Mulls Raising Pay for US Execs MT
Chart Smith & Nephew Plc
More charts
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows: - orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders); - sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.; - wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc. The United States accounts for 53.7% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.2 USD
Average target price
16.43 USD
Spread / Average Target
+34.68%
Consensus
  1. Stock Market
  2. Equities
  3. SN. Stock
  4. News Smith & Nephew Plc
  5. Smith & Nephew Says UK NICE Reaffirms Guidance on Pico Wound Dressing